Welcome to our dedicated page for Greenwich LifeSciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich LifeSciences stock.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company dedicated to the development of groundbreaking immunotherapies aimed at preventing breast cancer recurrences. The company's flagship product, GP2, is an immunotherapy designed to stimulate the body's immune system to target and eliminate HER2/neu-expressing cancer cells, particularly in patients who have already undergone surgery for breast cancer.
GP2 leverages the HER2/neu transmembrane peptide to elicit a targeted immune response, providing a promising approach to cancer treatment. Another significant component of their pipeline is the GM-CSF Immunoadjuvant, which has shown potential in enhancing monocyte and neutrophil cytotoxicity against melanoma tumor cells, as well as boosting activity-dependent cellular cytotoxicity against targets coated with anti-ganglioside antibodies.
The company’s ongoing clinical trials are a testament to its commitment to innovation and excellence in cancer treatment. These trials are being conducted in collaboration with a steering committee comprising esteemed members from various medical institutions, ensuring rigorous oversight and adherence to the highest standards of clinical research.
Greenwich LifeSciences places a strong emphasis on advancing cancer immunotherapy to selectively stimulate an individual's immune system to attack cancer cells, thereby inhibiting the spread of the disease. Their work not only focuses on breast cancer but extends to other cancer types, showcasing a broad potential for impact in oncology.
With a robust pipeline, strategic partnerships, and a clear focus on unmet medical needs, Greenwich LifeSciences is poised to be a leader in the biopharmaceutical industry. Investors and stakeholders can stay updated on the latest developments and company performance through regular news updates and reports.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, reports its significant achievements, including a 763% increase in share price since its IPO in February 2019, the highest among 307 biotech IPOs. The company is pleased with H.C. Wainwright's analyst coverage initiation on September 1, 2021, with a price target of $78 per share. It has also been added to the Russell 2000 index, enhancing its visibility to institutional investors. Upcoming updates on GP2 immunotherapy and Phase III clinical trial initiation are anticipated.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced its participation in Citi's 16th Annual BioPharma Virtual Conference, taking place from September 8-10, 2021. CEO Snehal Patel will engage in one-on-one meetings with investors. The conference features key discussions and presentations from leading pharma and biotech companies. Greenwich focuses on developing GP2, an immunotherapy aimed at preventing breast cancer recurrences. Previous Phase IIb trials showed no recurrences in high HER2 positive patients after treatment, and a Phase III trial is planned.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced its inclusion in the Russell 2000® and Russell 3000® Indexes effective June 28, 2021. This milestone is expected to boost institutional ownership and visibility for the company as it develops GP2, an immunotherapy aimed at preventing breast cancer recurrences. CEO Snehal Patel emphasized the significance of this addition and the plans for a Phase III clinical trial. The Russell Indexes are benchmarks for $10.6 trillion in assets, highlighting the potential for increased interest in GLSI.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) presented the final 5-year safety data of its GP2 immunotherapy at the 2021 ASCO Annual Meeting. The Phase IIb trial showed no serious adverse events related to GP2, with the majority experiencing mild injection site reactions. Notably, completion of the GP2 Primary Immunization Series led to a 0% recurrence rate in HER2 3+ patients over five years post-surgery. The findings support plans for a Phase III trial, leveraging the encouraging safety data to attract potential partners for co-development.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has appointed Christine Fischette, Ph.D., as Vice President of Business Development. Dr. Fischette aims to expand the company’s pipeline and pursue strategic partnerships for its immunotherapy product, GP2, which has shown promising results in preventing breast cancer recurrences. The final safety data from a Phase IIb trial will be presented at the upcoming ASCO conference, which, if positive, could enhance GP2's market appeal. CEO Snehal Patel emphasized that Dr. Fischette's experience will be vital as they target new breast cancer markets.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has announced the publication of a second poster detailing the GP2 Phase III clinical trial design at the 2021 AACR Annual Meeting. Led by Dr. Mothaffar F. Rimawi, the trial aims to treat up to 500 patients to evaluate GP2 as an immunotherapy to prevent breast cancer recurrences post-surgery. The trial is based on promising Phase IIb results showing 100% invasive Disease-Free Survival (iDFS) after 5 years. An interim analysis is planned, and the trial will explore expanding the treatment for various HLA types.
Greenwich LifeSciences (Nasdaq: GLSI) presented final immune response data from a 5-year Phase IIb clinical trial of GP2, an immunotherapy for preventing breast cancer recurrences, at the 2021 AACR Annual Meeting. The study showed that those completing the GP2 treatment had a 0% recurrence rate over five years. Significant peak immunity was achieved after 6 months of GP2 treatment, with positive immune responses observed in both HER2 3+ and HER2 1-2+ populations. These results suggest potential broader applications for GP2 in treating other HER2-related cancers.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced the final 5-year immune response data from its Phase IIb clinical trial at the 2021 AACR Annual Meeting. This data is crucial for developing dosing strategies for GP2, an immunotherapy aimed at preventing breast cancer recurrences. The AACR published the data abstract on April 9, with a poster to be released on April 10. Additional updates on Phase III trial design are expected the week of April 12, and safety data presentations are scheduled for the ASCO conference on June 4.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced CEO Snehal Patel's participation in the Benzinga Biotech Small-Cap Conference on March 24, 2021. He will be involved in a 30-minute immunotherapy oncology panel at 10:25 am EST and a live 15-minute presentation at 12:35 pm EST, followed by a Q&A session. The company is focused on developing GP2, an immunotherapy intended to prevent breast cancer recurrences in previously treated patients. The Phase IIb trial showed promising results with no recurrences after five years.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced acceptance of two abstracts for presentation at the virtual AACR Annual Meeting 2021, scheduled for April 10-15. The first abstract features five-year immune response data from the Phase IIb clinical trial, critical for finalizing Phase III trial designs. CEO Snehal Patel noted that GP2 manufacturing is on track for completion in mid-2021, with patient enrollment in Phase III expected by late 2021. The company aims to assess HER2/neu responses for potential combined therapies.
FAQ
What is the current stock price of Greenwich LifeSciences (GLSI)?
What is the market cap of Greenwich LifeSciences (GLSI)?
What is Greenwich LifeSciences, Inc.?
What is GP2?
What does the GM-CSF Immunoadjuvant do?
What types of cancer is Greenwich LifeSciences targeting?
Who oversees the clinical trials at Greenwich LifeSciences?
What is the significance of HER2/neu in cancer treatment?
Are there any ongoing clinical trials?
How can investors stay updated on the company?
What makes Greenwich LifeSciences' approach unique?
Where can I find more information about Greenwich LifeSciences?
